The portable ATUSA™ System reportedly provides 3D ultrasound visualization of the entire breast volume in two minutes.
A new modality that may redefine the efficiency of breast imaging has received 510(k) clearance from the Food and Drug Administration (FDA). The new ATUSA™ System, a portable whole breast ultrasound device, can provide 3D imaging in two minutes, according to iSono Health, the manufacturer of the device.
Featuring intuitive software designed to integrate with machine learning models, the ATUSA system provides efficient automated scans of breast volume and analysis. Emphasizing patient comfort, the ultrasound device also offers a compact portability with a unique wearable accessory.
“A portable and automated whole breast ultrasound augmented with machine learning would be the most practical technology to reduce breast cancer mortality globally, specifically in countries with limited resources. In developed countries, ultrasound has proven effective as an adjunct to mammography to improve breast cancer diagnosis in women with dense breasts,” noted Mohammad Eghtedari, M.D., Ph.D., a breast radiologist and assistant professor at the University of California-San Diego. “I believe iSono Health’s automated and portable technology will improve access to breast care for women worldwide and empower physicians with insightful data to make more informed clinical decisions.
The ATUSA system also facilitates consistent, reproducible accuracy, regardless of the experience level of the physician, Maryam Ziaei, Ph.D., the co-founder and CEO of iSonoHealth
“Clinicians and women worldwide need high quality breast imaging that is accessible and efficient at scale without the need for highly skilled operators,” emphasized Maryam Ziaei, Ph.D, the co-founder and CEO of iSonoHealth. “The portable and automated ATUSA system stands alone in comparison to other ultrasound offerings in promising to address that need.”
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
FDA Clears Point-Of-Care Ultrasound Platform and AI Software for Neuraxial Procedures
July 17th 2025The dual FDA clearances for the Accuro 3S point-of-care ultrasound device and the SpineNav-AI machine learning-based software may enhance precision and safety with ultrasound-guided neuraxial procedures.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.